Straumann® SLActive®

Performance beyond imagination.

Immediate loading

High predictability
in immediate loading
Learn More

Faster osseointegration*,1

To enhance confidence
in all treatments
Learn More

*Compared to SLA. Based on results of a preclinical study in animals (fox hounds); the preclinical testing is not correlated to long-term clinical outcomes in humans.

Enhanced bone formation**,2

Significantly higher formation of new bone aggregate
Learn More

**Based on results of a pre-clinical study in animals (mini-pig). The pre-clinical testing is not correlated to long-term clinical outcomes in human.

Promote osseointegration

In a recently published pre-clinical study4 SLActive® outperformed TiUltra™ in 5 out of 6 parameters of osseointegration and direct bone apposition after 8 weeks of healing.
Read the Publication

TiUltra™  is a registered trademark of Nobel Biocare Services AG, Switzerland

Setting the standard for success.
Performance beyond imagination.

Together with leading clinicians worldwide, Straumann has studied the clinical performance of SLActive implants under challenging treatment protocols to demonstrate the outstanding healing capacity of the SLActive surface.

As new insights emerge and new data becomes available, discover how you can benefit from the truly phenomenal performance of SLActive to maximize your patients’ healing capabilities.

Implant survival rate in immediate
loading after 10 years3


Randomized controlled multicenter study (96 patients, 127 implants)

Immediate loading

with long-lasting results.

Immediate loading allows the clinician to place a prosthetic restoration on the same day as the implant. However, this demanding protocol carries a higher risk of failure due to premature loading of a healing implant.

Learn why
  • Long-term data from a randomized, controlled, multicenter study demonstrates impressive performance of SLActive® with immediate loading.
  • In fact, the SLActive implants delivered a 10-year survival rate of 98.2 % in this challenging protocol.3
Download the SLActive brochure

Enhanced bone regeneration.

Even at compromised sites.

Enhanced bone grafting**
Bone defects can greatly compromise the predictability of osseointegration.

In a recent preclinical study2, SLActive showed significantly higher formation of new bone aggregate within eight weeks compared to the standard Straumann® SLA® hydrophobic surface.

**Based on results of a preclinical study in animals (minipig). The pre-clinical testing is not correlated to long-term clinical outcomes in humans.

Bone aggregate formation at 8 weeks.

botiss cerabone®

SLA®

SLActive®

Allograft

SLA®

SLActive®

Histological views of bone aggregate
(new bone and grafting material) 8 weeks post-grafting

**Based on results of a pre-clinical study in animals (minipig); the preclinical testing
is not correlated to long-term clinical outcomes in humans.

Contact Us to Learn More

Straumann collects your information to facilitate the commercial relationship, contact you regarding future product offerings and promotion and all other permissible business purposes. Please see our Privacy Policy for more information.

Downloads

Documents

References

1 Straumann SLActive implants compared to Straumann SLA implants.
2 Straumann (2016). SLActive supports enhanced bone formation in a minipig surgical GBR model with coronal circumferential defects. Unpublished data.
3 Nicolau P, Guerra F, Reis R, Krafft T, Benz K , Jackowski J 10-year results from a randomized controlled multicenter study with immediately and early loaded SLActive implants in posterior jaws. Accepted for oral presentation at 25th Annual Scientific Meeting of the European Association of Osseointegration – 29 Sep – 1 Oct 2016, Paris.
4 Shahdad S. et al. Benchmark performance of anodized vs. sandblasted implant surfaces in an acute dehiscence type defect animal model. Clin Oral Implants Res. 2022 Sep 19.